CasNo.107868-30-4,Anti tumor drug 99% Exemestane/Aromasin powder BP/USP Standard,(107868-30-4) Suppliers

100 Gram	Negotiable

Min.Order :100 Gram
Purity: 99%
Payment Terms : T/T,

Keywords

Exemestane Aromasin Powder Exemestane powder

Quick Details

Appearance:white powder
Application:pharmaceuticals
PackAge:1Kgs/Tin,25Kgs/Carton
ProductionCapacity:500|Metric Ton|Day
Storage:
Transportation:

Superiority:

GMP Factory, cheap Price

Details:

Product Description of Anti tumor drug 99% Exemestane/Aromasin powder CAS 107868-30-4

Name: exemestane
CAS Number: 107868-30-4
Molecular formula: C20H24O2
Molecular weight: 296.40300
Exact Mass: 296.17800
PSA: 34.14000
LogP: 4.02950

Physicochemical properties

Appearance and traits: white to pale yellow crystalline powder
Density: 1.13 g/cm3
Melting point: 155.13°C
Boiling point: 453.7oC at 760 mmHg
Flash point: 169oC
Refractive index: 1.572
Storage conditions: Store in original container in a cool dark place.
Steam pressure: 2.02E-08mmHg at 25°C

Specification:

TEST ITEMS	SPECIFICATION	RESULTS
Description	: White Crystalline Powder	White Powder
Identification	: Positive	Positive
Assay(by HPLC)	: 98.0~102.0%	98.64%
Absorbance(E1cm)	: 465~495	482.5
Melting Point	: 191~195°C	193.5~195.0°C
Loss On Drying	: 0.5%max	0.19%
Specific Rotation	: +288°~ +298°	+290.2°
Residue On Ignition	: 0.1%max	0.03%
Related Substances	: Total:1.5%max	<1.3%
	Single:0.5%max	<0.4%
Residue Solvents	: 0.2%max	0.10%
Heavy Metals	: 20PPm max	<10PPm

Conclusion	The specification conform with enterprise standard.

Use

1. Second-generation aromatase inhibitors for the treatment of metastatic breast cancer and as an adjunct to early breast cancer.
2. Developed by Pharmacia & Upjohn Company. Approved by the U.S. FDA in October 1997. Antineoplastic Agent, Second Generation Aromatase Inhibitor. Exemestane is the first oral hormonal agent that can be selectively targeted and permanently In combination with aromatase, once exemestane binds to the enzyme, the enzyme can never be remade estrogen. It can inhibit the supply of estrogen to cancer cells and help prevent cells from continuing to grow. It is used to treat metastatic disease. Breast cancer and its use as an adjunct to early breast cancer.
3. This product is a second-generation aromatase inhibitor. It can be irreversibly combined with aromatase to inactivate it, thus preventing the biosynthesis of estrogen. Clinically for the treatment of metastatic breast cancer and early breast cancer Adjuvant therapy with exact curative effect, good tolerability and relatively few side effects